je.st
news
Tag: hpv
Too few teens receiving HPV vaccinations, CDC says
2014-07-25 14:27:30| Biotech - Topix.net
Unacceptably low numbers of teens are getting vaccinated for the human papillomavirus, or HPV, which protects against cervical, throat and mouth cancers, according to the Centers for Disease Control and Prevention.
Tags: says
receiving
teens
cdc
CDC recalls HPV vaccine due to risk of glass particles in vials
2013-12-22 17:01:31| Biotech - Topix.net
And now one lot of the Gardasil vaccine has been recalled due to a risk of having glass particles in the vials.
Tags: due
risk
glass
particles
Parental Attitudes on Teen Sex Stymie Use of HPV Vaccination
2013-11-26 08:02:21| Biotech - Topix.net
Parental concern that getting vaccinated for the human papillomavirus may increase teenagers' sexual activity is among the attitudes discouraging use of the inoculation to prevent cervical cancer, researchers found.
Tags: sex
teen
attitudes
parental
Mercks Investigational 9-valent HPV Vaccine, V503, Prevented 97 Percent of Cervical, Vaginal and Vulvar Pre-cancers Caused by Five Additional HPV Types, in Phase III Study
2013-11-04 13:30:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. Immunogenicity non-inferior to GARDASIL for original four HPV types Merck expects to file Biologics License Application with U.S. FDA in 2013 WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that in the pivotal Phase III efficacy study, its investigational 9-valent HPV vaccine (V503) prevented approximately 97 percent of cervical, vaginal and vulvar pre-cancers caused by HPV types 31, 33, 45, 52, and 58. Language: English Contact: Media:Pamela Eisele, 908-423-5042orImraan Munshi, 215-652-0059orInvestor:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: in
additional
study
iii
Merck Provides Update on Investigational 9-valent HPV Vaccine V503 to U.S. Advisory Committee on Immunization Practices
2013-10-24 16:27:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today provided an overview of the clinical trial program for V503, the companys investigational 9-valent human papillomavirus (HPV) vaccine, to the Advisory Committee on Immunization Practices in the United States. Merck said that the pivotal efficacy trial is complete, the primary endpoints have been met and the company expects to submit a Biologics License Application for V503 to the U.S. Language: English Contact: MerckMedia:Pamela Eisele, (908) 423-5042Imraan Munshi, (215) 652-0059Investor:Carol Ferguson, (908) 423-4465Justin Holko, (908) 423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: update
committee
practices
advisory